Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-26T16:14:22.524Z Has data issue: false hasContentIssue false

Chapter 3 - Substance Use Stigma and Policy

Published online by Cambridge University Press:  23 June 2022

By
Emma E. McGinty  and
Sarah A. White
Edited by
Georg Schomerus  and
Patrick William Corrigan
Georg Schomerus
Affiliation:
Universität Leipzig
Patrick William Corrigan
Affiliation:
Illinois Institute of Technology
Get access

Summary

The pervasive stigma surrounding nonmedical substance use and substance use disorder relates to policy along multiple bidirectional pathways. To meaningfully reduce substance use stigma, we need members of the public to be able to readily identify positive examples of people benefiting from evidence-based substance use services and thriving in their daily lives. To saturate the public with these types of positive examples, public and institutional policies must shift to support widespread delivery of effective substance use interventions, including prevention, treatment, and harm reduction approaches. This chapter introduces a conceptual framework for delineating key ways in which stigma and policy relate to one another; synthesizes the evidence on what is known about the relationship between substance use stigma and policy; and discusses the evidence surrounding strategies to reduce stigma and increase support for policies benefiting people who use substances and/or experience substance use disorder.

Keywords

stigmapolicylegislationstatuteregulationinstitutional policy
Type
Chapter
Information
The Stigma of Substance Use Disorders , pp. 23 - 45
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abdul-Quader, A. S., Feelemyer, J., Modi, S., et al. (2013). Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic review. AIDS and Behavior, 17(9), 2878–2892.Google Scholar
Allen, S. T., Grieb, S. M., O’Rourke, A., et al. (2019). Understanding the public health consequences of suspending a rural syringe services program: A qualitative study of the experiences of people who inject drugs. Harm Reduction Journal, 16(1), Article 33.Google Scholar
Andraka-Christou, B., & Capone, M. J. (2018). A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. International Journal of Drug Policy, 54, 9–17.Google Scholar
Ashford, R. D., Brown, A. M., & Curtis, B. (2018). Substance use, recovery, and linguistics: The impact of word choice on explicit and implicit bias. Drug and Alcohol Dependence, 189, 131–138.Google Scholar
Bachhuber, M. A., McGinty, E. E., Kennedy-Hendricks, A., Niederdeppe, J., & Barry, C. L. (2015). Messaging to increase public support for naloxone distribution policies in the United States: Results from a randomized survey experiment. PLOS ONE, 10(7), e0130050.Google Scholar
Bandara, S. N., McGinty, E. E., & Barry, C. L. (2020). Message framing to reduce stigma and increase support for policies to improve the wellbeing of people with prior drug convictions. International Journal of Drug Policy, 76, Article 102643.CrossRefGoogle ScholarPubMed
Barry, C. L. (2018). Fentanyl and the evolving opioid epidemic: What strategies should policy makers consider? Psychiatric Services, 69(1), 100–103.Google Scholar
Barry, C. L., Kennedy‐Hendricks, A., Gollust, S. E., et al. (2016). Understanding Americans’ views on opioid pain reliever abuse. Addiction, 111(1), 85–93.Google Scholar
Barry, C. L., & McGinty, E. E. (2014). Stigma and public support for parity and government spending on mental health: A 2013 National Opinion Survey. Psychiatric Services, 65(10), 1265–1268.Google Scholar
Barry, C. L., McGinty, E. E., Pescosolido, B. A., & Goldman, H. H. (2014). Stigma, discrimination, treatment effectiveness, and policy: Public views about drug addiction and mental illness. Psychiatric Services, 65(10), 1269–1272.Google Scholar
Beetham, T., Saloner, B., Wakeman, S. E., Gaye, M., & Barnett, M. L. (2019). Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality. Annals of Internal Medicine, 171(1), 1–9.Google Scholar
Beletsky, L., Macalino, G. E., & Burris, S. (2005). Attitudes of police officers towards syringe access, occupational needle-sticks, and drug use: A qualitative study of one city police department in the United States. International Journal of Drug Policy, 16(4), 267–274.Google Scholar
Bernstein, S. E., & Bennett, D. (2013). Zoned out: “NIMBYism”, addiction services and municipal governance in British Columbia. International Journal of Drug Policy, 24(6), e61–e65.Google Scholar
Bessen, S., Metcalf, S. A., Saunders, E. C., et al. (2019). Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA. International Journal of Drug Policy, 74, 144–151.Google Scholar
Bornstein, M., Berger, A., & Gipson, J. D. (2020). A mixed methods study exploring methadone treatment disclosure and perceptions of reproductive health care among women ages 18–44 years, Los Angeles, CA. Journal of Substance Abuse Treatment, 118, Article 108119.Google Scholar
Burris, S., Beletsky, L., Castagna, C., & Coyle, C. (2009). Stopping an invisible epidemic: Legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Review, 1, 273–340.Google Scholar
Calabrese, C., & Bell, R. A. (2019). Opposition to nonprescription naloxone access: Measurement and psychosocial predictors. Substance Use & Misuse, 54(11), 1853–1861.Google Scholar
Cole, J. M. (2013). Guidance regarding marijuana enforcement [Memorandum]. United States Department of Justice, Office of the Deputy Attorney General. www.justice.gov/iso/opa/resources/3052013829132756857467.pdfGoogle Scholar
Cooper, H. L., Cloud, D. H., Freeman, P. R., et al. (2020). Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. International Journal of Drug Policy, 85, Article 102701.Google Scholar
Corrigan, P. W., Kuwabara, S. A., & O’Shaughnessy, J. (2009). The public stigma of mental illness and drug addiction. Journal of Social Work, 9(2), 139–147.Google Scholar
Corrigan, P. W., & Nieweglowski, K. (2018). Stigma and the public health agenda for the opioid crisis in America. International Journal of Drug Policy, 59, 44–49.Google Scholar
Crandall, C. S., Eshleman, A., & O’Brien, L. (2002). Social norms and the expression and suppression of prejudice: The struggle for internalization. Journal of Personality and Social Psychology, 82(3), 359–378.Google Scholar
Crotty, K., Freedman, K. I., & Kampman, K. M. (2020). Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder. Journal of Addiction Medicine, 14(2), 99–112.Google Scholar
Cruz, M. F., Patra, J., Fischer, B., Rehm, J., & Kalousek, K. (2007). Public opinion towards supervised injection facilities and heroin-assisted treatment in Ontario, Canada. International Journal of Drug Policy, 18(1), 54–61.Google Scholar
Ellis, K., Walters, S., Friedman, S. R., et al. (2020). Breaching trust: A qualitative study of healthcare experiences of people who use drugs in a rural setting. Frontiers in Sociology, 5.Google Scholar
Fiscella, K., Wakeman, S. E., & Beletsky, L. (2019). Buprenorphine deregulation and mainstreaming treatment for opioid use disorder. JAMA Psychiatry, 76(3), 229–230.Google Scholar
Gollust, S. E., & Miller, J. M. (2020). Framing the opioid crisis: Do racial frames shape beliefs of whites losing ground? Journal of Health Politics, Policy and Law, 45(2), 241–276.Google Scholar
Goodyear, K., & Chavanne, D. (2021). Stigma and policy preference toward individuals who transition from prescription opioids to heroin. Addictive Behaviors, 115, Article 106784.CrossRefGoogle ScholarPubMed
Green, T. C., Zaller, N., Palacios, W. R., et al. (2013). Law enforcement attitudes toward overdose prevention and response. Drug and Alcohol Dependence, 133(2), 677–684.Google Scholar
Gross, K. (2008). Framing persuasive appeals: Episodic and thematic framing, emotional response, and policy opinion. Political Psychology, 29(2), 169–192.Google Scholar
Harris, J., & McElrath, K. (2012). Methadone as social control. Qualitative Health Research, 22(6), 810–824.Google Scholar
Hatzenbuehler, M. L. (2016). Structural stigma: Research evidence and implications for psychological science. American Psychological, 71(8), 742–751.CrossRefGoogle ScholarPubMed
Iyengar, S. (1990). Framing responsibility for political issues: The case of poverty. Political Behavior, 12(1), 19–40.Google Scholar
Iyengar, S. (1996). Framing responsibility for political issues. The ANNALS of the American Academy of Political and Social Science, 546(1), 59–70.Google Scholar
Jauffret-Roustide, M., Pedrono, G., & Beltzer, N. (2013). Supervised consumption rooms: The French Paradox. International Journal of Drug Policy, 24(6), 628–630.Google Scholar
Jones, C. M. (2019). Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S. International Journal of Drug Policy, 70, 22–32.Google Scholar
Kelly, J. F., Saitz, R., & Wakeman, S. (2016). Language, substance use disorders, and policy: The need to reach consensus on an “addiction-ary”. Alcoholism Treatment Quarterly, 34(1), 116–123.Google Scholar
Kennedy, M. C., Karamouzian, M., & Kerr, T. (2017). Public health and public order outcomes associated with supervised drug consumption facilities: A systematic review. Current HIV/AIDS Reports, 14(5), 161–183.Google Scholar
Kennedy-Hendricks, A., Barry, C. L., Gollust, S. E., Ensminger, M. E., Chisolm, M. S., & McGinty, E. E. (2017). Social stigma toward persons with prescription opioid use disorder: Associations with public support for punitive and public health–oriented policies. Psychiatric Services, 68(5), 462–469.Google Scholar
Kennedy-Hendricks, A., Barry, C. L., Stone, E., Bachhuber, M. A., & McGinty, E. E. (2020). Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians. Drug and Alcohol Dependence, 216, Article 108217.Google Scholar
Kennedy-Hendricks, A., Busch, S. H., McGinty, E. E., et al. (2016). Primary care physicians’ perspectives on the prescription opioid epidemic. Drug and Alcohol Dependence, 165, 61–70.Google Scholar
Kennedy-Hendricks, A., McGinty, E. E., & Barry, C. L. (2016). Effects of competing narratives on public perceptions of opioid pain reliever addiction during pregnancy. Journal of Health Politics, Policy and Law, 41(5), 873–916.Google Scholar
Kerr, T., Mitra, S., Kennedy, M. C., & McNeil, R. (2017). Supervised injection facilities in Canada: Past, present, and future. Harm Reduction Journal, 14(1), Article 28.Google Scholar
Knopf, A. (2019). ASAM supports eliminating the x‐waiver for buprenorphine. Alcoholism & Drug Abuse Weekly, 31(29), 6–7.Google Scholar
Krawczyk, N., Picher, C. E., Feder, K. A., & Saloner, B. (2017). Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Affairs, 36(12), 2046–2053.CrossRefGoogle ScholarPubMed
Kruis, N. E., & Merlo, A. V. (2020). A preliminary assessment of stigma in law enforcement officers’ responses to opioid overdoses. Journal of Drug Issues, 51(2), 301–322.Google Scholar
Kulesza, M., Teachman, B. A., Werntz, A. J., Gasser, M. L., & Lindgren, K. P. (2015). Correlates of public support toward federal funding for harm reduction strategies. Substance Abuse Treatment, Prevention, and Policy, 10(1), Article 25.Google Scholar
Lancaster, K., Santana, L., Madden, A., & Ritter, A. (2015). Stigma and subjectivities: Examining the textured relationship between lived experience and opinions about drug policy among people who inject drugs. Drugs: Education, Prevention and Policy, 22(3), 224–231.Google Scholar
Link, B. G., Phelan, J. C., Bresnahan, M., Stueve, A., & Pescosolido, B. A. (1999). Public conceptions of mental illness: Labels, causes, dangerousness, and social distance. American Journal of Public Health, 89(9), 1328–1333.Google Scholar
Livingston, J. D., Milne, T., Fang, M. L., & Amari, E. (2012). The effectiveness of interventions for reducing stigma related to substance use disorders: A systematic review. Addiction, 107(1), 39–50.Google Scholar
Luoma, J. B., Twohig, M. P., Waltz, T., et al. (2007). An investigation of stigma in individuals receiving treatment for substance abuse. Addictive Behaviors, 32(7), 1331–1346.Google Scholar
Madden, E. F. (2019). Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Social Science & Medicine, 232, 324–331.Google Scholar
Marino, R., Perrone, J., Nelson, L. S., et al. (2019). ACMT position statement: Remove the waiver requirement for prescribing buprenorphine for opioid use disorder. Journal of Medical Toxicology, 15(4), 307–309.Google Scholar
Matheson, C., Jaffray, M., Ryan, M., et al. (2014). Public opinion of drug treatment policy: Exploring the public’s attitudes, knowledge, experience and willingness to pay for drug treatment strategies. International Journal of Drug Policy, 25(3), 407–415.Google Scholar
McGinty, E., & Barry, C. L. (2020). Stigma reduction to combat the addiction crisis – developing an evidence base. New England Journal of Medicine, 382(14), 1291–1292.Google Scholar
McGinty, E., Barry, C. L., Stone, E. M., et al. (2018). Public support for safe consumption sites and syringe services programs to combat the opioid epidemic. Preventive Medicine, 111, 73–77.Google Scholar
McGinty, E., Goldman, H. H., Pescosolido, B., & Barry, C. L. (2015). Portraying mental illness and drug addiction as treatable health conditions: Effects of a randomized experiment on stigma and discrimination. Social Science & Medicine, 126, 73–85.Google Scholar
McGinty, E., Pescosolido, B., Kennedy-Hendricks, A., & Barry, C. L. (2018). Communication strategies to counter stigma and improve mental illness and substance use disorder policy. Psychiatric Services, 69(2), 136–146.Google Scholar
McNeely, J., Kumar, P. C., Rieckmann, T., et al. (2018). Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: A qualitative study of patients, providers, and staff. Addiction Science & Clinical Practice, 13(1), Article 8.Google Scholar
McNeil, R., & Small, W. (2014). ‘Safer environment interventions’: A qualitative synthesis of the experiences and perceptions of people who inject drugs. Social Science & Medicine, 106, 151–158.Google Scholar
Mehta, S., & Farina, A. (2011). Is being “sick” really better? Effect of the disease view of mental disorder on stigma. Journal of Social and Clinical Psychology, 16(4), 405–419.Google Scholar
Mendiola, C. K., Galetto, G., & Fingerhood, M. (2018). An exploration of emergency physicians’ attitudes toward patients with substance use disorder. Journal of Addiction Medicine, 12(2), 132–135.Google Scholar
Meyerson, B. E., Lawrence, C. A., Cope, S. D., et al. (2019). I could take the judgment if you could just provide the service: Non-prescription syringe purchase experience at Arizona pharmacies, 2018. Harm Reduction Journal, 16(1), Article 57.CrossRefGoogle ScholarPubMed
Mojtabai, R., Mauro, C., Wall, M. M., Barry, C. L., & Olfson, M. (2019). Medication treatment for opioid use disorders in substance use treatment facilities. Health Affairs, 38(1), 14–23.Google Scholar
Mojtabai, R., Mauro, C., Wall, M. M., Barry, C. L., & Olfson, M. (2020). Private health insurance coverage of drug use disorder treatment: 2005–2018. PLOS ONE, 15(10), e0240298.Google Scholar
Murphy, J., & Russell, B. (2020). Police officers’ views of naloxone and drug treatment: Does greater overdose response lead to more negativity? Journal of Drug Issues, 50(4), 455–471.CrossRefGoogle Scholar
National Academies of Sciences, Education, and Medicine [NASEM]. (2019). Medications for opioid use disorder save lives. Washington, DC: The National Academies Press.Google Scholar
National Conference of State Legislatures. (2021). State medical marijuana laws. Retrieved February 24, 2021 from www.ncsl.org/research/health/state-medical-marijuana-laws.aspxGoogle Scholar
Niederdeppe, J., Kim, H. K., Lundell, H., Fazili, F., & Frazier, B. (2012). Beyond counterarguing: Simple elaboration, complex integration, and counterelaboration in response to variations in narrative focus and sidedness. Journal of Communication, 62(5), 758–777.Google Scholar
Niederdeppe, J., Shapiro, M. A., Kim, H. K., Bartolo, D., & Porticella, N. (2014). Narrative persuasion, causality, complex integration, and support for obesity policy. Health Communication, 29(5), 431–444.Google Scholar
Olsen, Y., & Sharfstein, J. M. (2014). Confronting the stigma of opioid use disorder – and its treatment. JAMA, 311(14), 1393–1394.Google Scholar
Pescosolido, B. A., & Martin, J. K. (2015). The stigma complex. Annual Review of Sociology, 41(1), 87–116.Google Scholar
Pescosolido, B. A., Martin, J. K., Long, J. S., Medina, T. R., Phelan, J. C., & Link, B. G. (2010). “A disease like any other”? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. American Journal of Psychiatry, 167(11), 1321–1330.CrossRefGoogle ScholarPubMed
Pollack Porter, K. M., Rutkow, L., & McGinty, E. E. (2018). The importance of policy change for addressing public health problems. Public Health Reports, 133(1_suppl), 9S–14S.Google Scholar
Richard, E. L., Schalkoff, C. A., Piscalko, H. M., et al. (2020). “You are not clean until you’re not on anything”: Perceptions of medication-assisted treatment in rural Appalachia. International Journal of Drug Policy, 85, Article 102704.Google Scholar
Romer, D., & Bock, M. (2008). Reducing the stigma of mental illness among adolescents and young adults: The effects of treatment information. Journal of Health Communication, 13(8), 742–758.Google Scholar
Rutkow, L., Smith, K. C., Lai, A. Y., Vernick, J. S., Davis, C. S., & Alexander, G. C. (2017). Prescription drug monitoring program design and function: A qualitative analysis. Drug and Alcohol Dependence, 180, 395–400.Google Scholar
Saloner, B., Bandara, S., Bachhuber, M., & Barry, C. L. (2017). Insurance coverage and treatment use under the Affordable Care Act among adults with mental and substance use disorders. Psychiatric Services, 68(6), 542–548.Google Scholar
Saloner, B., Stoller, K. B., & Alexander, G. C. (2018). Moving addiction care to the mainstream – improving the quality of buprenorphine treatment. New England Journal of Medicine, 379(1), 4–6.Google Scholar
Samet, J. H., Botticelli, M., & Bharel, M. (2018). Methadone in primary care – one small step for Congress, one giant leap for addiction treatment. New England Journal of Medicine, 379(1), 7–8.Google Scholar
Schneider, A., & Ingram, H. (1993). Social construction of target populations: Implications for politics and policy. American Political Science Review, 87(2), 334–347.Google Scholar
Schnittker, J. (2008). An uncertain revolution: Why the rise of a genetic model of mental illness has not increased tolerance. Social Science & Medicine, 67(9), 1370–1381.Google Scholar
Schomerus, G., Matschinger, H., & Angermeyer, M. C. (2006). Alcoholism: Illness beliefs and resource allocation preferences of the public. Drug and Alcohol Dependence, 82, 204–210.Google Scholar
Schomerus, G., Matschinger, H., & Angermeyer, M. C. (2014). Casual beliefs of the public and social acceptance of persons with mental illness: A comparative analysis of schizophrenia, depression, and alcohol dependence. Psychological Medicine, 44, 303–314.Google Scholar
Skinner, N., Feather, N. T., Freeman, T., & Roche, A. (2007). Stigma and discrimination in health-care provision to drug users: The role of values, affect, and deservingness judgments. Journal of Applied Social Psychology, 37(1), 163–186.Google Scholar
Smith, C. B. R. (2010). Socio-spatial stigmatization and the contested space of addiction treatment: Remapping strategies of opposition to the disorder of drugs. Social Science & Medicine, 70(6), 859–866.Google Scholar
Stein, B. D., Sorbero, M., Dick, A. W., Pacula, R. L., Burns, R. M., & Gordon, A. J. (2016). Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA, 316(11), 1211–1212.Google Scholar
Stone, E. M., Kennedy-Hendricks, A., Barry, C. L., Bachhuber, M. A., & McGinty, E. E. (2021). The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder. Drug and Alcohol Dependence, 221, Article 108627.Google Scholar
Stone, E. M., Rutkow, L., Bicket, M. C., Barry, C. L., Alexander, G. C., & McGinty, E. E. (2020). Implementation and enforcement of state opioid prescribing laws. Drug and Alcohol Dependence, 213, Article 108107.Google Scholar
Strike, C., & Miskovic, M. (2017). Zoning out methadone and rising opioid-related deaths in Ontario: Reforms and municipal government actions. Canadian Journal of Public Health, 108(2), e205–e207.Google Scholar
Substance Abuse and Mental Health Services Administration [SAMHSA] (2020). Medications for opioid use disorder. Treatment improvement protocol (TIP) series No. 63 (Publication No. PEP20–02-01-006). https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP20-02-01-006Google Scholar
Terplan, M., Kennedy-Hendricks, A., & Chisolm, M. S. (2015). Article commentary: Prenatal substance use: Exploring assumptions of maternal unfitness. Substance Abuse: Research and Treatment, 9s2, Article SART.S23328.Google Scholar
Thomas, S., Treffers, R., Berglas, N. F., Drabble, L., & Roberts, S. C. M. (2018). Drug use during pregnancy policies in the United States from 1970 to 2016. Contemporary Drug Problems, 45(4), 441–459.Google Scholar
Tsai, A. C., Kiang, M. V., Barnett, M. L., et al. (2019). Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLOS Medicine, 16(11), e1002969.Google Scholar
Van Boekel, L. C., Brouwers, E. P. M., Van Weeghel, J., & Garretsen, H. F. L. (2013). Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug and Alcohol Dependence, 131(1–2), 23–35.Google Scholar
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-assisted therapies – tackling the opioid-overdose epidemic. New England Journal of Medicine, 370(22), 2063–2066.Google Scholar
Wakeman, S. E., & Rich, J. D. (2018). Barriers to medications for addiction treatment: How stigma kills. Substance Use & Misuse, 53(2), 330–333.Google Scholar
Woo, J., Bhalerao, A., Bawor, M., et al. (2017). “Don’t judge a book by its cover”: A qualitative study of methadone patients’ experiences of stigma. Substance Abuse: Research and Treatment, 11(0), Article 117822181668508.Google Scholar
Woodruff, A. E., Tomanovich, M., Beletsky, L., Salisbury-Afshar, E., Wakeman, S., & Ostrovsky, A. (2019). Dismantling buprenorphine policy can provide more comprehensive addiction treatment. NAM Perspectives. https://nam.edu/dismantling-buprenorphine-policy-can-provide-more-comprehensive-addiction-treatment/Google Scholar
Yarborough, B. J. H., Stumbo, S. P., McCarty, D., Mertens, J., Weisner, C., & Green, C. A. (2016). Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug and Alcohol Dependence, 160, 112–118.Google Scholar
Yuanhong Lai, A., Smith, K. C., Vernick, J. S., Davis, C. S., Caleb Alexander, G., & Rutkow, L. (2019). Perceived unintended consequences of prescription drug monitoring programs. Substance Use & Misuse, 54(2), 345–349.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×